EUVIMEDEUVIMED entdecken
Leserbrief

Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB)

Dawd S Siraj iD, Fauzia Hollnagel iD

Journal of Gastroenterology and Hepatology · 2026-06 · 41 (6) · 1919-1920

DOI: 10.1111/jgh.70398 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 16.04.2026. Verfasst von Dawd S Siraj und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin, Madison, Wisconsin, USA. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • University of Wisconsin, Madison, Wisconsin, USA.

ORCID-Profile: Dawd S Siraj, Fauzia Hollnagel

Zitieren

APA

Siraj, D. S., & Hollnagel, F. (2026). Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB). Journal of Gastroenterology and Hepatology, 41(6), 1919-1920. https://doi.org/10.1111/jgh.70398

Vancouver

Siraj DS, Hollnagel F. Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB). Journal of Gastroenterology and Hepatology. 2026;41(6):1919-1920. doi:10.1111/jgh.70398

BibTeX
@article{Siraj2026,
  author = {Siraj, Dawd S and Hollnagel, Fauzia},
  title = {Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB)},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {6},
  pages = {1919--1920},
  doi = {10.1111/jgh.70398}
}
Kostenlos starten →